Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage (Q44889298)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

7 December 2017

Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage (English)

1 reference

Europe PubMed Central

7 December 2017

author name string

Qigui Yu

1

1 reference

Europe PubMed Central

7 December 2017

Brad Jones

2

1 reference

Europe PubMed Central

7 December 2017

Ningjie Hu

3

1 reference

Europe PubMed Central

7 December 2017

Hong Chang

4

1 reference

Europe PubMed Central

7 December 2017

Sidrah Ahmad

5

1 reference

Europe PubMed Central

7 December 2017

Jun Liu

6

1 reference

Europe PubMed Central

7 December 2017

Mark Parrington

7

1 reference

Europe PubMed Central

7 December 2017

Mario Ostrowski

8

1 reference

Europe PubMed Central

7 December 2017

language of work or name

0 references

publication date

30 June 2006

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

24

1 reference

Europe PubMed Central

7 December 2017

40-41

1 reference

Europe PubMed Central

7 December 2017

6376-6391

1 reference

Europe PubMed Central

7 December 2017

Vaccinia and other poxvirus expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Roles of vaccinia virus in the development of new vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccinia virus expression vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Viruses as vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Poxvirus tropism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Smallpox vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV inf

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Highly attenuated poxvirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Susceptibility of different leukocyte cell types to Vaccinia virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected indivi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

CD33/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Regulation of Toll-like receptor (TLR)2 and TLR4 on CD14dimCD16+ monocytes in response to sepsis-related antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Safety profile of recombinant canarypox HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Role of therapeutic vaccines in the control of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.06.011

7 January 2021

Identifiers

10.1016/J.VACCINE.2006.06.011

1 reference

Europe PubMed Central

7 December 2017

1 reference

Europe PubMed Central

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44889298&oldid=2055821506"